news
Scmp World
2026-11-07
FDA probes potential tumor risks associated with Novartis gene therapy Zolgensma
The US Food and Drug Administration is investigating reports of tumor formation in children treated with Novartis' spinal muscular atrophy drug, Zolgensma.